Research ExplorerPublicationsImpact of Everolimus and Low-Dose Cyclosporin on Cytomegalov...

Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation

Standard

Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. / Höcker, B; Zencke, S; Pape, L; Krupka, K; Köster, L; Fichtner, A; Dello Strologo, L; Guzzo, I; Topaloglu, R; Kranz, B; König, J; Bald, M; Webb, N J A; Noyan, A; Dursun, H; Marks, S; Ozcakar, Z B; Thiel, F; Billing, H; Pohl, M; Fehrenbach, H; Schnitzler, P; Bruckner, T; Ahlenstiel-Grunow, T; Tönshoff, B.

In: AM J TRANSPLANT, Vol. 16, No. 3, 03.2016, p. 921-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Höcker, B, Zencke, S, Pape, L, Krupka, K, Köster, L, Fichtner, A, Dello Strologo, L, Guzzo, I, Topaloglu, R, Kranz, B, König, J, Bald, M, Webb, NJA, Noyan, A, Dursun, H, Marks, S, Ozcakar, ZB, Thiel, F, Billing, H, Pohl, M, Fehrenbach, H, Schnitzler, P, Bruckner, T, Ahlenstiel-Grunow, T & Tönshoff, B 2016, 'Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation', AM J TRANSPLANT, vol. 16, no. 3, pp. 921-9. https://doi.org/10.1111/ajt.13649

APA

Höcker, B., Zencke, S., Pape, L., Krupka, K., Köster, L., Fichtner, A., Dello Strologo, L., Guzzo, I., Topaloglu, R., Kranz, B., König, J., Bald, M., Webb, N. J. A., Noyan, A., Dursun, H., Marks, S., Ozcakar, Z. B., Thiel, F., Billing, H., ... Tönshoff, B. (2016). Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. AM J TRANSPLANT, 16(3), 921-9. https://doi.org/10.1111/ajt.13649

Vancouver

Höcker B, Zencke S, Pape L, Krupka K, Köster L, Fichtner A et al. Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. AM J TRANSPLANT. 2016 Mar;16(3):921-9. https://doi.org/10.1111/ajt.13649

Bibtex

@article{2d3e518c19f3437291ae402d03038e53,
title = "Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation",
abstract = "In order to investigate the hypothesis that the mammalian target of rapamycin inhibitor everolimus (EVR) shows anticytomegalovirus (CMV) activity in pediatric patients, we analyzed the impact of EVR-based immunosuppressive therapy on CMV replication and disease in a large cohort (n = 301) of pediatric kidney allograft recipients. The EVR cohort (n = 59), who also received low-dose cyclosporin, was compared with a control cohort (n = 242), who was administered standard-dose cyclosporin or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%). Multivariate analysis revealed an 83% lower risk of CMV replication in the EVR cohort than in the control cohort (p = 0.005). In CMV high-risk (donor+/recipient-) patients (n = 88), the EVR-based regimen was associated with a significantly lower rate of CMV disease (0% vs. 14.3%, p = 0.046) than the standard regimen. In patients who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 year and 3 years posttransplant (100%) were significantly (p = 0.015) higher in the EVR cohort (n = 15) than in the control cohort (n = 48; 1 year, 75.0%; 3 years, 63.3%). Our data suggest that in pediatric patients at high risk of CMV, an EVR-based immunosuppressive regimen is associated with a lower risk of CMV disease than a standard-dose calcineurin inhibitor-based regimen.",
keywords = "Child, Cyclosporine, Cytomegalovirus, Cytomegalovirus Infections, Everolimus, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection, Graft Survival, Humans, Immunosuppression, Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Function Tests, Kidney Transplantation, Male, Postoperative Complications, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Virus Replication, Journal Article, Research Support, Non-U.S. Gov't",
author = "B H{\"o}cker and S Zencke and L Pape and K Krupka and L K{\"o}ster and A Fichtner and {Dello Strologo}, L and I Guzzo and R Topaloglu and B Kranz and J K{\"o}nig and M Bald and Webb, {N J A} and A Noyan and H Dursun and S Marks and Ozcakar, {Z B} and F Thiel and H Billing and M Pohl and H Fehrenbach and P Schnitzler and T Bruckner and T Ahlenstiel-Grunow and B T{\"o}nshoff",
note = "{\textcopyright} Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.",
year = "2016",
month = mar,
doi = "10.1111/ajt.13649",
language = "English",
volume = "16",
pages = "921--9",
journal = "AM J TRANSPLANT",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation

AU - Höcker, B

AU - Zencke, S

AU - Pape, L

AU - Krupka, K

AU - Köster, L

AU - Fichtner, A

AU - Dello Strologo, L

AU - Guzzo, I

AU - Topaloglu, R

AU - Kranz, B

AU - König, J

AU - Bald, M

AU - Webb, N J A

AU - Noyan, A

AU - Dursun, H

AU - Marks, S

AU - Ozcakar, Z B

AU - Thiel, F

AU - Billing, H

AU - Pohl, M

AU - Fehrenbach, H

AU - Schnitzler, P

AU - Bruckner, T

AU - Ahlenstiel-Grunow, T

AU - Tönshoff, B

N1 - © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

PY - 2016/3

Y1 - 2016/3

N2 - In order to investigate the hypothesis that the mammalian target of rapamycin inhibitor everolimus (EVR) shows anticytomegalovirus (CMV) activity in pediatric patients, we analyzed the impact of EVR-based immunosuppressive therapy on CMV replication and disease in a large cohort (n = 301) of pediatric kidney allograft recipients. The EVR cohort (n = 59), who also received low-dose cyclosporin, was compared with a control cohort (n = 242), who was administered standard-dose cyclosporin or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%). Multivariate analysis revealed an 83% lower risk of CMV replication in the EVR cohort than in the control cohort (p = 0.005). In CMV high-risk (donor+/recipient-) patients (n = 88), the EVR-based regimen was associated with a significantly lower rate of CMV disease (0% vs. 14.3%, p = 0.046) than the standard regimen. In patients who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 year and 3 years posttransplant (100%) were significantly (p = 0.015) higher in the EVR cohort (n = 15) than in the control cohort (n = 48; 1 year, 75.0%; 3 years, 63.3%). Our data suggest that in pediatric patients at high risk of CMV, an EVR-based immunosuppressive regimen is associated with a lower risk of CMV disease than a standard-dose calcineurin inhibitor-based regimen.

AB - In order to investigate the hypothesis that the mammalian target of rapamycin inhibitor everolimus (EVR) shows anticytomegalovirus (CMV) activity in pediatric patients, we analyzed the impact of EVR-based immunosuppressive therapy on CMV replication and disease in a large cohort (n = 301) of pediatric kidney allograft recipients. The EVR cohort (n = 59), who also received low-dose cyclosporin, was compared with a control cohort (n = 242), who was administered standard-dose cyclosporin or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%). Multivariate analysis revealed an 83% lower risk of CMV replication in the EVR cohort than in the control cohort (p = 0.005). In CMV high-risk (donor+/recipient-) patients (n = 88), the EVR-based regimen was associated with a significantly lower rate of CMV disease (0% vs. 14.3%, p = 0.046) than the standard regimen. In patients who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 year and 3 years posttransplant (100%) were significantly (p = 0.015) higher in the EVR cohort (n = 15) than in the control cohort (n = 48; 1 year, 75.0%; 3 years, 63.3%). Our data suggest that in pediatric patients at high risk of CMV, an EVR-based immunosuppressive regimen is associated with a lower risk of CMV disease than a standard-dose calcineurin inhibitor-based regimen.

KW - Child

KW - Cyclosporine

KW - Cytomegalovirus

KW - Cytomegalovirus Infections

KW - Everolimus

KW - Female

KW - Follow-Up Studies

KW - Glomerular Filtration Rate

KW - Graft Rejection

KW - Graft Survival

KW - Humans

KW - Immunosuppression

KW - Immunosuppressive Agents

KW - Kidney Failure, Chronic

KW - Kidney Function Tests

KW - Kidney Transplantation

KW - Male

KW - Postoperative Complications

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Survival Rate

KW - Virus Replication

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/ajt.13649

DO - 10.1111/ajt.13649

M3 - SCORING: Journal article

C2 - 26613840

VL - 16

SP - 921

EP - 929

JO - AM J TRANSPLANT

JF - AM J TRANSPLANT

SN - 1600-6135

IS - 3

ER -